Prof. Zhang specializes in clinical work of oncology radiotherapy and combination therapy, and relevant radiation and molecular biological studies, especially radiotherapy and research of gastrointestinal tumors and soft tissue sarcoma such as lymphoma, breast cancer, gastric cancer and pancreatic cancer.

Work experience

1995-1999: Served as a physician and attending physician in the Department of Radiotherapy, Cancer Center of Qilu Hospital of Shandong University;

2002-present: associate chief physician of Radiation Oncology at Sun Yat-sen University Cancer Center;

2008-2009: Conducted research work at Texas Children's Cancer Center of Baylor College of Medicine;

2010-2011: Guest doctor and supporting expert for the Department of Breast and Thoracoabdomine at Cancer Hospital of Xinjiang Medical University.

Prof. Zhang specializes in clinical work of oncology radiotherapy, especially radiotherapy and combination therapy for lymphoma, breast cancer, gastropancreatic tumor, and soft tissue sarcoma. He has been engaging himself in the clinical and relevant researches of the above-mentioned cancer in renowned cancer centers at home and abroad, accumulating abundant experiences from his 20 years of clinical practices. He conducts in-depth researches of radiotherapy of breast cancer and radiotherapy indications of early breast cancer; masters and has unique insights into diagnosis and treatment of extranodal NK/T-cell lymphoma, nasal type, and primary extranodal lymphoma in locations such as Waldeyer's tonsillar ring, gastrointestine, bone, breast and orbit; takes the lead in adopting new IMRT for radiotherapy and combination therapy for gastric cancer and pancreatic cancer.

 

He had undertaken doctoral and postdoctoral researches in the field of oncology molecular radiobiology in a renowned cancer laboratory, research interest including radiobiology of high LET ray, regulation and control of radiosensitivity of cancer stem cells, individualized prediction of radiation effects of cancer tissue and normal tissue and etc.

1995-2000: Doctoral student of radiation oncology at Cancer Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College

1. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31(3):860.
2. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ*. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumor Biology. 2014; 35(3): 2141-2149.
3. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ*. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.  Int J Hematol. 2012; 96(5):617-623.
4. Iyengar P, Strom EA, Zhang YJ, Whitman GJ, Smith BD, Woodward WA, Yu TK, Buchholz TA.  The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist. 2012; 17(11):1402-1408.
5. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma.  Neuro Oncol. 2012; 14(5):574-583.
6. Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO. Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys. 2012; 83(1): 284-291.
7. Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011; 13(1): 14-27.
8. Zhang YJ, Oh JL, Whitman GJ, Iyengar P, Yu TK, Tereffe W, Woodward WA, Perkins G, Buchholz TA, Strom EA. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys. 2010; 77(4): 1113-1119.
9. Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM, Su JM, Perlaky L, Dauser R, Chintagumpala M, Lau CC, Blaney SM, Rao PH, Leung HC, Li XN. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010; 12(6): 580-594.
10. Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008; 3(8): 858-64.

Updated by International Office, Sun Yat-sen University Cancer Center